Back to top

healthcare: Archive

Kaibalya Pravo Dey

Is UnitedHealth's Valuation Dip & Divestment Diet a Real Buy Window?

UNH trades below its five-year median P/E as it navigates margin pressure, membership declines and strategic divestments.

UNHPositive Net Change HUMPositive Net Change ELVNegative Net Change

Rajshree Sipani

Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)

CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.

UNHPositive Net Change CVSNegative Net Change

Rajshree Sipani

Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?

CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.

UNHPositive Net Change CVSNegative Net Change

Urmimala Biswas

Demographic Megatrend: Stocks Poised to Benefit From Global Aging

Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.

BSXNegative Net Change AMGNPositive Net Change EWNegative Net Change OHINegative Net Change ABBVPositive Net Change CTREPositive Net Change ENSGNegative Net Change

Kaibalya Pravo Dey

UnitedHealth Recovers Its Rhythm Before Q3 Earnings: Time to Buy?

UNH's Q3 results hinge on premium growth and Optum gains amid rising costs and margin pressure.

UNHPositive Net Change HUMPositive Net Change MOHPositive Net Change

Kaibalya Pravo Dey

UNH vs. HUM: Which Healthcare Stock is the Healthier Buy Now?

Humana's sharper Medicare focus, cost discipline and leaner structure position it ahead of UnitedHealth in the healthcare stock race.

UNHPositive Net Change HUMPositive Net Change

Urmimala Biswas

Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains

Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.

ABTNegative Net Change BSXNegative Net Change MDTNegative Net Change

Kaibalya Pravo Dey

UnitedHealth Jumps 12% in a Month: But is it Healthy Enough to Buy?

UNH surges 12% in a month, but with rising costs and regulatory pressures, is now the time to buy or wait?

UNHPositive Net Change BRK.BNegative Net Change HUMPositive Net Change ELVNegative Net Change

Kaibalya Pravo Dey

UnitedHealth vs. Molina: Who's Poised for the Healthiest Comeback?

Health insurers are facing turbulence, but which stock is set to rebound stronger: the diversified giant UNH or Medicaid-focused MOH?

UNHPositive Net Change BRK.BNegative Net Change MOHPositive Net Change

Kaibalya Pravo Dey

UnitedHealth Reaffirms 2025 EPS Guidance: Time to Buy or Wait?

UNH reaffirms its 2025 EPS outlook, but mounting costs, legal probes and valuation pressures cloud the path ahead.

UNHPositive Net Change BRK.BNegative Net Change MOHPositive Net Change CNCNo Net Change

Urmimala Biswas

Investing in the Age of Longevity: Silver Economy Stocks in Focus

AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.

ABTNegative Net Change AMGNPositive Net Change MDTNegative Net Change SYKNegative Net Change DXCMPositive Net Change ABBVPositive Net Change

Urmimala Biswas

Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?

BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.

AZNPositive Net Change NVDANegative Net Change BFLYPositive Net Change TEMPositive Net Change

Urmimala Biswas

Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?

Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.

IRTCPositive Net Change SOPHNegative Net Change TEMPositive Net Change

Kaibalya Pravo Dey

When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline

ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.

UNHPositive Net Change CNCNo Net Change ELVNegative Net Change

Urmimala Biswas

Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?

CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.

UNHPositive Net Change CVSNegative Net Change HLFNo Net Change

Kaibalya Pravo Dey

UnitedHealth Crashing After Q2 Shock: Should You Panic or Pounce?

UNH plunges 12.9% after weak Q2 and slashing 2025 EPS guidance, sparking fears of deeper structural issues ahead.

UNHPositive Net Change MOHPositive Net Change CNCNo Net Change

Urmimala Biswas

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.

AZNPositive Net Change TXGNegative Net Change SOPHNegative Net Change TEMPositive Net Change

Urmimala Biswas

Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

AZNPositive Net Change NVOPositive Net Change NVDANegative Net Change TEMPositive Net Change

Urmimala Biswas

CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?

CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.

UNHPositive Net Change CVSNegative Net Change

Kaibalya Pravo Dey

UnitedHealthcare Pressure Builds: Trouble Ahead for UNH's Q2 Earnings?

UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.

UNHPositive Net Change HUMPositive Net Change MOHPositive Net Change

Kaibalya Pravo Dey

UnitedHealth on Thin Ice Before Q2 Earnings: Should Investors Exit?

UNH braces for a 27% earnings drop in Q2 as soaring medical costs, margin pressure and investor jitters weigh on performance.

UNHPositive Net Change HUMPositive Net Change MOHPositive Net Change

Urmimala Biswas

CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?

Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.

UNHPositive Net Change CVSNegative Net Change HLFNo Net Change

Urmimala Biswas

TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

AZNPositive Net Change IRTCPositive Net Change SOPHNegative Net Change TEMPositive Net Change

Urmimala Biswas

CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?

CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.

UNHPositive Net Change CINegative Net Change CVSNegative Net Change

Urmimala Biswas

Smart Money Going in Senior Health: Key Stocks in Elderly Care

RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.

ABTNegative Net Change RHHBYPositive Net Change NVOPositive Net Change MDTNegative Net Change SYKNegative Net Change EWNegative Net Change